Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

Table 2

Plasma IL-17A concentration in studied group of patients.

Group of patients	Plasma IL-17A concentration (pg/ml)
	Median	Minimum	Maximum
Ovarian cancer (n = 71)	3.80	0.042	30.00
Benign tumors (n = 35)	0.229	0.076	1.696
Control group (n = 10)	0.533	0.076	1.295

compared to both the group of benign ovarian tumors and the control. Clinical significance of IL-17A in the plasma and peritoneal fluid of OC patients.